A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | MicrobiomeTrials
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2024-08-14Est. Completion: 2031-09-09
Enrollment target: 58 participants
Locations
UCLA Medical Center, Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Mayo Clinic - Rochester, Rochester, Minnesota, United States
Uni Of TX MD Anderson Cancer Cntr, Houston, Texas, United States
University Of Wisconsin, Madison, Wisconsin, United States
Novartis Investigative Site, Darlinghurst, New South Wales, Australia
Novartis Investigative Site, Malvern, Victoria, Australia